The asx does not rate medtech like the NASDAQ does.I am into AVR as well and they are going to the NASDAQ in the next 6 months as per their agm in order to raise more money and not to be confined by a 15% asx ruling. If they gain 5% of the $10b market they are in and be priced as per their rivals they would have a SP of $600. Presently $19. They like EYE have a better product than the market leader Edwards science as per the data.
The asx does not rate medtech like the NASDAQ does.I am into AVR...
-
- There are more pages in this discussion • 199 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $35.50M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $51.14K | 322.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 143500 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 95380 | 4 |
View Market Depth
| Last trade - 12.17pm 12/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |